NSEBSECOMMODITYNASDAQNYSEFOREXINDICESAMEXUSA More...

CRNX announcements Crinetics Pharmaceuticals, Inc. announcements and dividends declared NASDAQ

Crinetics Pharmaceuticals, Inc. Complete list of announcements declared & dividend announcements by Crinetics Pharmaceuticals, Inc. CRNX

Crinetics Pharmaceuticals, Inc. CRNX listed on NASDAQ and deals in Health Care Major Pharmaceuticals

Announcements and dividends declared by Crinetics Pharmaceuticals, Inc. CRNX

Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
Crinetics Pharmaceuticals, Inc. (CRNX) shares ended the last trading session 19.1% higher at .18. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to
Announcement as on 20 March 2024

Crinetics Pharmaceuticals (FRA:6Z4) Price Target Increased by 11.73% to 48.98
The average one-year price target for Crinetics Pharmaceuticals (FRA:6Z4) has been revised to 48.98 / share. This is an increase of 11.73% from the prior estimate of 43.84 dated August 31, 2023. The price target is an average of many targets provided by a
Announcement as on 06 October 2023

: Crinetics Pharmaceuticals shares surge 65%, analysts raise price target after acromegaly treatment results
Shares of Crinetics Pharmaceuticals Inc. CRNX gained 65% premarket on Monday after the company announced positive results from a late-stage study of paltusotine, its investigational treatment for acromegaly. The phase 3 trial met the primary endpoint and a
Announcement as on 11 September 2023

: Crinetics Pharmaceuticals shares rise as analysts see ‘drug hunters in their zone’
Shares of Crinetics Pharmaceuticals Inc. CRNX gained more than 4% premarket on Thursday after Oppenheimer analysts initiated coverage of the shares with an outperform rating, calling Crinetics ‘drug hunters in their zone.’ Crinetics focuses on developi
Announcement as on 31 August 2023

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of [CO].85 per share versus the Zacks Consensus Estimate of a loss of [CO].82. This compares to loss of [CO].73 per share a year ago. These figures are adjusted for non-recurring items.
Announcement as on 04 May 2023

Announcements by Crinetics Pharmaceuticals, Inc. first page | Next page |

CRNX Crinetics Pharmaceuticals, Inc. current price & indicator signals